Tonix Pharmaceuticals stock halted ahead of FDA approval news
On Monday, H.C. Wainwright analyst reaffirmed a Buy rating and a $21.00 price target for PDS Biotechnology Corp (NASDAQ:PDSB) shares, representing significant upside from the current price of $1.23. According to InvestingPro data, analyst targets for PDSB range from $4.50 to $21.00, with the company currently valued at $46 million. The biopharmaceutical company recently announced the initiation of its Phase 3 VERSATILE-003 study, aiming to assess the effectiveness and safety of its Versamune HPV treatment in combination with pembrolizumab as a first-line therapy for recurrent or metastatic HPV16-positive head and neck squamous cell carcinoma (HNSCC). InvestingPro analysis shows the company maintains a healthy current ratio of 2.84, with more cash than debt on its balance sheet, providing runway for this crucial clinical development.
The trial is a global, multi-center, randomized, open-label pivotal study designed to enroll approximately 350 patients. Participants will be divided into two groups: one receiving Versamune HPV with pembrolizumab and a control group receiving pembrolizumab alone, at a 2:1 ratio. The primary goal of the study is to measure overall survival (OS), with secondary endpoints including objective response rate (ORR), progression-free survival (PFS), disease control rate (DCR), and duration of response (DoR).
H.C. Wainwright’s endorsement comes on the heels of the earlier VERSATILE-002 study, a single-arm Phase 2 trial that also investigated the combination of Versamune HPV and pembrolizumab in the same medical condition. The results from VERSATILE-002 suggested that the combination therapy could offer significant clinical benefits, particularly in terms of the objective response rate and survival metrics.
The analyst expressed optimism about the potential of Versamune HPV, indicating that the previous study results may lower the risks associated with late-stage clinical development. This, in turn, could set the stage for Versamune HPV to become the first targeted immunotherapy for HNSCC, should it demonstrate success in the VERSATILE-003 study. The reiterated Buy rating and price target reflect the firm’s confidence in the therapy’s prospects. With a beta of 1.67 and recent stock volatility, InvestingPro subscribers can access 13 additional key insights about PDSB’s financial health and market position through the comprehensive Pro Research Report.
In other recent news, PDS Biotechnology Corporation has initiated a Phase 3 clinical trial named VERSATILE-003, targeting HPV16-positive head and neck cancer. This trial will assess the safety and efficacy of their immunotherapy, Versamune® HPV, in combination with pembrolizumab against pembrolizumab alone. The trial design received FDA approval, allowing the company to proceed with site activation expected in the first quarter of 2025. Additionally, PDS Biotech announced an $11 million direct offering with healthcare-focused institutional investors, intending to use the proceeds for research and development and general corporate purposes. The offering involves the sale of over 7.3 million shares and warrants, with an exercise price of $1.50 per share. The company has emphasized that its forward-looking statements are subject to risks and uncertainties, advising investors to review these in conjunction with their SEC filings. Dr. Frank Bedu-Addo, President and CEO, and Dr. Kirk Shepard, Chief Medical (TASE:BLWV) Officer, have both expressed optimism about the potential impact of their immunotherapy on patient outcomes. These developments reflect PDS Biotech’s ongoing efforts to advance treatment options for patients with advanced HPV16-positive head and neck squamous cell carcinoma.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.